Beaulieu, Pierre Boulanger, Aline Desroches, Julie and Clark, Alexander J. 2016. Medical cannabis: considerations for the anesthesiologist and pain physician. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, Vol. 63, Issue. 5, p. 608.
Davis, Justin Eyre, Harris Jacka, Felice N Dodd, Seetal Dean, Olivia McEwen, Sarah Debnath, Monojit McGrath, John Maes, Michael Amminger, Paul McGorry, Patrick D Pantelis, Christos and Berk, Michael 2016. A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience & Biobehavioral Reviews, Vol. 65, p. 185.
Ksir, Charles and Hart, Carl L. 2016. Cannabis and Psychosis: a Critical Overview of the Relationship. Current Psychiatry Reports, Vol. 18, Issue. 2,
Marconi, Arianna Di Forti, Marta Lewis, Cathryn M. Murray, Robin M. and Vassos, Evangelos 2016. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin, Vol. 42, Issue. 5, p. 1262.
Murray, Robin M. Quigley, Harriet Quattrone, Diego Englund, Amir and Di Forti, Marta 2016. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry, Vol. 15, Issue. 3, p. 195.
Nesvåg, Ragnar Reichborn-Kjennerud, Ted Gillespie, Nathan A. Knudsen, Gun Peggy Bramness, Jørgen G. Kendler, Kenneth S. and Ystrom, Eivind 2016. Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins. Schizophrenia Bulletin, p. sbw101.
Rentzsch, Johannes Stadtmann, Ada Montag, Christiane Kunte, Hagen Plöckl, Doris Hellweg, Rainer Gallinat, Jürgen Kronenberg, Golo and Jockers-Scherübl, Maria Christiane 2016. Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, Issue. 5, p. 409.
Volk, David W. and Lewis, David A. 2016. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological Psychiatry, Vol. 79, Issue. 7, p. 595.
Bhavsar, Vishal 2015. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia. Evidence Based Mental Health, Vol. 18, Issue. 3, p. 84.
Bhui, K. Ullrich, S. Kallis, C. and Coid, J. W. 2015. Criminal justice pathways to psychiatric care for psychosis. The British Journal of Psychiatry, Vol. 207, Issue. 6, p. 523.
Danielsson, Anna-Karin Falkstedt, Daniel Hemmingsson, Tomas Allebeck, Peter and Agardh, Emilie 2015. Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study. Addiction, Vol. 110, Issue. 11, p. 1794.
Deogan, Charlotte Zarabi, Natalie Stenström, Nils Högberg, Pi Skärstrand, Eva Manrique-Garcia, Edison Neovius, Kristian and Månsdotter, Anna 2015. Cost-Effectiveness of School-Based Prevention of Cannabis Use. Applied Health Economics and Health Policy, Vol. 13, Issue. 5, p. 525.
Guloksuz, S. van Nierop, M. Lieb, R. van Winkel, R. Wittchen, H.-U. and van Os, J. 2015. Evidence that the presence of psychosis in non-psychotic disorder is environment-dependent and mediated by severity of non-psychotic psychopathology. Psychological Medicine, Vol. 45, Issue. 11, p. 2389.
Hadland, Scott E. Knight, John R. and Harris, Sion K. 2015. Medical Marijuana. Journal of Developmental & Behavioral Pediatrics, Vol. 36, Issue. 2, p. 115.
Harper, Sarah Towers-Evans, Helen and MacCabe, James 2015. The aetiology of schizophrenia: what have the Swedish Medical Registers taught us?. Social Psychiatry and Psychiatric Epidemiology, Vol. 50, Issue. 10, p. 1471.
Manseau, Marc W. and Goff, Donald C. 2015. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics, Vol. 12, Issue. 4, p. 816.
Michaels, Timothy I and Novakovic, Vladan 2015. Can Cannabis Cause Psychosis?. Clinical Neuropharmacology, Vol. 38, Issue. 2, p. 63.
Sarrazin, Samuel Louppe, Florence Doukhan, Raphael and Schürhoff, Franck 2015. A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches. Annals of General Psychiatry, Vol. 14, Issue. 1,
Shrivastava, Amresh Johnston, Megan Terpstra, Kristen and Bureau, Yves 2015. Pathways to Psychosis in Cannabis Abuse. Clinical Schizophrenia & Related Psychoses, Vol. 9, Issue. 1, p. 30.
Spechler, Philip A. Orr, Catherine A. Chaarani, Bader Kan, Kees-Jan Mackey, Scott Morton, Aaron Snowe, Mitchell P. Hudson, Kelsey E. Althoff, Robert R. Higgins, Stephen T. Cattrell, Anna Flor, Herta Nees, Frauke Banaschewski, Tobias Bokde, Arun L.W. Whelan, Robert Büchel, Christian Bromberg, Uli Conrod, Patricia Frouin, Vincent Papadopoulos, Dimitri Gallinat, Jurgen Heinz, Andreas Walter, Henrik Ittermann, Bernd Gowland, Penny Paus, Tomáš Poustka, Luise Martinot, Jean-Luc Artiges, Eric Smolka, Michael N. Schumann, Gunter and Garavan, Hugh 2015. Cannabis use in early adolescence: Evidence of amygdala hypersensitivity to signals of threat. Developmental Cognitive Neuroscience, Vol. 16, p. 63.
There is now strong evidence that cannabis use increases the risk of psychoses including schizophrenia, but the relationship between cannabis and different psychotic disorders, as well as the mechanisms, are poorly known. We aimed to assess types of psychotic outcomes after use of cannabis in adolescence and variation in risk over time.
A cohort of 50 087 military conscripts with data on cannabis use in late adolescence was followed up during 35 years with regard to in-patient care for psychotic diagnoses.
Odds ratios for psychotic outcomes among frequent cannabis users compared with non-users were 3.7 [95% confidence interval (CI) 2.3–5.8] for schizophrenia, 2.2 (95% CI 1.0–4.7) for brief psychosis and 2.0 (95% CI 0.8–4.7) for other non-affective psychoses. Risk of schizophrenia declined over the decades in moderate users but much less so in frequent users. The presence of a brief psychosis did not increase risk of later schizophrenia more in cannabis users compared with non-users.
Our results confirm an increased risk of schizophrenia in a long-term perspective, although the risk declined over time in moderate users.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.